Top Markets
Coin of the day
Altamira Therapeutics Ltd. Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTO
주식 순위 #38206
Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new... Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.
주가
$0.3
마지막 동기화: 2026-02-10
시가총액
$1.13M
변동 (1일)
0.00%
변동 (1년)
328.57%
국가
BM
거래 Altamira Therapeutics Ltd. (CYTO)

카테고리

Altamira Therapeutics Ltd. (CYTO)의 배당 이력
Altamira Therapeutics Ltd. (주식 심볼: CYTO)은 총 0회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): 0.00
배당 수익률 (TTM): 0
Altamira Therapeutics Ltd. (CYTO)의 2026부터 2026까지 배당 지급 내역
연간 배당 지급
연도 배당금 (주식 분할 조정됨) 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
모든 배당 지급 목록
연도 배당금 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 지급